علاج سرطان الخلايا الحرشفية الشرجية مع مرض النقيلي خارج الحوض

Systemic therapy is generally recommended for extrapelvic metastatic disease.

Although further studies of PD-1/PD-L1 inhibitors are warranted, the panel added nivolumab and pembrolizumab as preferred options for patients with metastatic anal cancer who have experienced progression on first-line chemotherapy in the 2018 version of these guidelines.

The panel also notes that platinum-based chemotherapy should not be given in second line if disease progressed on platinum-based therapy in first line.